vs
Side-by-side financial comparison of Enhabit, Inc. (EHAB) and IDEX Corporation (IEX). Click either name above to swap in a different company.
IDEX Corporation is the larger business by last-quarter revenue ($398.4M vs $270.4M, roughly 1.5× Enhabit, Inc.). IDEX Corporation runs the higher net margin — 30.1% vs -14.3%, a 44.4% gap on every dollar of revenue. On growth, IDEX Corporation posted the faster year-over-year revenue change (16.7% vs 4.7%). IDEX Corporation produced more free cash flow last quarter ($86.0M vs $3.3M). Over the past eight quarters, Enhabit, Inc.'s revenue compounded faster (1.5% CAGR vs -29.4%).
Enhabit, Inc., is a Dallas, Texas-based provider of home health and hospice services. The company operates 255 home health and 110 hospice locations in 34 states with a concentration in Texas, Alabama, Florida, Georgia, Oklahoma and Mississippi. Enhabit is the fourth-largest provider of home health services in the United States and is a leading provider of hospice services. The company was formed in 2022 when Encompass Health spun off its home health and hospice business.
IDEX can refer to several things, including:International Defence Exhibition, a biennial arms and defense technology sales exhibition IDEX Corporation, a publicly listed company that makes fluidics systems and specialty engineered products Ideanomics, a publicly traded company that trades under the IDEX ticker symbol.
EHAB vs IEX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $270.4M | $398.4M |
| Net Profit | $-38.7M | $120.0M |
| Gross Margin | — | 99.9% |
| Operating Margin | -12.3% | 43.3% |
| Net Margin | -14.3% | 30.1% |
| Revenue YoY | 4.7% | 16.7% |
| Net Profit YoY | 15.9% | 25.7% |
| EPS (diluted) | $-0.76 | $1.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | — | $398.4M | ||
| Q1 26 | — | $407.7M | ||
| Q4 25 | $270.4M | $899.1M | ||
| Q3 25 | $263.6M | $878.7M | ||
| Q2 25 | $266.1M | $865.4M | ||
| Q1 25 | $259.9M | $814.3M | ||
| Q4 24 | $258.2M | $862.9M | ||
| Q3 24 | $253.6M | $798.2M |
| Q2 26 | — | $120.0M | ||
| Q1 26 | — | $128.3M | ||
| Q4 25 | $-38.7M | $128.3M | ||
| Q3 25 | $11.1M | $127.8M | ||
| Q2 25 | $5.2M | $131.6M | ||
| Q1 25 | $17.8M | $95.5M | ||
| Q4 24 | $-46.0M | $123.2M | ||
| Q3 24 | $-110.2M | $119.1M |
| Q2 26 | — | 99.9% | ||
| Q1 26 | — | 94.9% | ||
| Q4 25 | — | 43.1% | ||
| Q3 25 | — | 44.5% | ||
| Q2 25 | — | 45.3% | ||
| Q1 25 | — | 45.3% | ||
| Q4 24 | — | 42.5% | ||
| Q3 24 | — | 44.3% |
| Q2 26 | — | 43.3% | ||
| Q1 26 | — | 45.0% | ||
| Q4 25 | -12.3% | 20.4% | ||
| Q3 25 | 6.4% | 21.1% | ||
| Q2 25 | 6.3% | 21.7% | ||
| Q1 25 | 6.1% | 17.4% | ||
| Q4 24 | -16.0% | 19.2% | ||
| Q3 24 | -38.6% | 21.0% |
| Q2 26 | — | 30.1% | ||
| Q1 26 | — | 31.5% | ||
| Q4 25 | -14.3% | 14.3% | ||
| Q3 25 | 4.2% | 14.5% | ||
| Q2 25 | 2.0% | 15.2% | ||
| Q1 25 | 6.8% | 11.7% | ||
| Q4 24 | -17.8% | 14.3% | ||
| Q3 24 | -43.5% | 14.9% |
| Q2 26 | — | $1.61 | ||
| Q1 26 | — | $1.71 | ||
| Q4 25 | $-0.76 | $1.71 | ||
| Q3 25 | $0.22 | $1.70 | ||
| Q2 25 | $0.10 | $1.74 | ||
| Q1 25 | $0.35 | $1.26 | ||
| Q4 24 | $-0.92 | $1.61 | ||
| Q3 24 | $-2.20 | $1.57 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $43.6M | $586.2M |
| Total DebtLower is stronger | $426.0M | — |
| Stockholders' EquityBook value | $534.0M | $4.0B |
| Total Assets | $1.2B | $6.9B |
| Debt / EquityLower = less leverage | 0.80× | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | $586.2M | ||
| Q1 26 | — | $580.0M | ||
| Q4 25 | $43.6M | $580.0M | ||
| Q3 25 | $56.9M | $593.8M | ||
| Q2 25 | $37.1M | $568.2M | ||
| Q1 25 | $39.5M | $594.1M | ||
| Q4 24 | $28.4M | $620.8M | ||
| Q3 24 | $45.7M | $633.2M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $426.0M | $1.8B | ||
| Q3 25 | $441.5M | $1.9B | ||
| Q2 25 | $456.9M | $1.9B | ||
| Q1 25 | $467.3M | $2.0B | ||
| Q4 24 | $492.6M | $2.0B | ||
| Q3 24 | $502.9M | $2.1B |
| Q2 26 | — | $4.0B | ||
| Q1 26 | — | $4.0B | ||
| Q4 25 | $534.0M | $4.0B | ||
| Q3 25 | $566.8M | $4.0B | ||
| Q2 25 | $552.4M | $4.0B | ||
| Q1 25 | $543.2M | $3.9B | ||
| Q4 24 | $523.5M | $3.8B | ||
| Q3 24 | $566.1M | $3.8B |
| Q2 26 | — | $6.9B | ||
| Q1 26 | — | $6.9B | ||
| Q4 25 | $1.2B | $6.9B | ||
| Q3 25 | $1.2B | $7.0B | ||
| Q2 25 | $1.2B | $6.9B | ||
| Q1 25 | $1.2B | $6.8B | ||
| Q4 24 | $1.2B | $6.7B | ||
| Q3 24 | $1.3B | $7.0B |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 0.80× | 0.45× | ||
| Q3 25 | 0.78× | 0.48× | ||
| Q2 25 | 0.83× | 0.46× | ||
| Q1 25 | 0.86× | 0.50× | ||
| Q4 24 | 0.94× | 0.52× | ||
| Q3 24 | 0.89× | 0.55× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.4M | — |
| Free Cash FlowOCF − Capex | $3.3M | $86.0M |
| FCF MarginFCF / Revenue | 1.2% | 21.6% |
| Capex IntensityCapex / Revenue | 0.4% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $65.8M | $654.3M |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $4.4M | $209.5M | ||
| Q3 25 | $37.8M | $203.5M | ||
| Q2 25 | $10.6M | $161.7M | ||
| Q1 25 | $17.9M | $105.7M | ||
| Q4 24 | $-4.1M | $172.6M | ||
| Q3 24 | $28.4M | $205.3M |
| Q2 26 | — | $86.0M | ||
| Q1 26 | — | $189.8M | ||
| Q4 25 | $3.3M | $189.8M | ||
| Q3 25 | $36.2M | $188.7M | ||
| Q2 25 | $8.7M | $146.9M | ||
| Q1 25 | $17.6M | $91.4M | ||
| Q4 24 | $-4.7M | $157.1M | ||
| Q3 24 | $27.7M | $191.6M |
| Q2 26 | — | 21.6% | ||
| Q1 26 | — | 46.6% | ||
| Q4 25 | 1.2% | 21.1% | ||
| Q3 25 | 13.7% | 21.5% | ||
| Q2 25 | 3.3% | 17.0% | ||
| Q1 25 | 6.8% | 11.2% | ||
| Q4 24 | -1.8% | 18.2% | ||
| Q3 24 | 10.9% | 24.0% |
| Q2 26 | — | 4.4% | ||
| Q1 26 | — | 15.6% | ||
| Q4 25 | 0.4% | 2.2% | ||
| Q3 25 | 0.6% | 1.7% | ||
| Q2 25 | 0.7% | 1.7% | ||
| Q1 25 | 0.1% | 1.8% | ||
| Q4 24 | 0.2% | 1.8% | ||
| Q3 24 | 0.3% | 1.7% |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 1.63× | ||
| Q3 25 | 3.41× | 1.59× | ||
| Q2 25 | 2.04× | 1.23× | ||
| Q1 25 | 1.01× | 1.11× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EHAB
| Third Party Payor Medicare | $111.6M | 41% |
| Third Party Payor Medicare Advantage | $67.5M | 25% |
| Hospice Segment | $63.6M | 24% |
| Third Party Payor Managed Care | $24.9M | 9% |
| Third Party Payor Medicaid | $1.7M | 1% |
IEX
Segment breakdown not available.
